Overview

Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects. Most notably, unnecessary right ventricular pacing can lead to an increase of 8% risk of heart failure death per 10% increase in right ventricular pacing.1 Furthermore, right ventricular pacing is associated with a 1% increase in risk of atrial fibrillation (AF) for each 1% increase in cumulative right ventricular pacing.2

Managed Ventricular Pacing (MVP™) reduces unnecessary right ventricular pacing by 99%.3


Summary of clinical trial data

Atrial-based pacing benefits Hospitalization for CHF
Atrial fibrillation

Danish I3

Atrial vs. ventricular pacing all sinus node disease

Decreased incident or relative risk

Decreased incident or relative risk

CTOPP4

AAI or DDD vs. ventricular pacing
~ 40% of patients had SND N = 2,568

Not studied

Decreased incident or relative risk

Danish II5

AAIR vs. DDDR + short AV delay or
DDDR + long AV delay AV delay
All SND patients N = 177

Not statistically significant

Decreased incident or relative risk

MOST sub-study6

DDDR vs. VVIR All SND patients
N = 1,339

Decreased incident or relative risk

Decreased incident or relative risk



Risk of AF2

Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of AF2,4–6 and heart failure hospitalization (HFH).2,4



How does MVP work?

The MVP™ modes promote intrinsic conduction by reducing unnecessary right ventricular pacing. These modes provide atrial-based pacing with ventricular backup. If AV conduction is lost, the device is designed to switch to DDDR or DDD mode. Periodic conduction checks are performed, and if AV conduction resumes, the device switches back to AAIR or AAI mode.

For detailed information regarding this algorithm, visit MedtronicAcademy.com.

This feature can be found in some Medtronic pacemaker, ICD, and CRT-D devices.


Continuous automatic conduction checks